Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 34,100 full-time employees.  The company is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its platforms comprise chemically synthesized or small molecule drugs, including protein degraders; drugs produced from biological processes, called biologics; ADCs, CAR-T cell therapies, and radiopharmaceutical therapeutics. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are also used. Biologics are typically administered through injections or by intravenous infusion. CAR-T cell therapies are administered by intravenous infusion. Its growth portfolio includes Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Opdualag, and others. Its legacy portfolio includes Eliquis, Revlimid, Pomalyst/Imnovid, Sprycel and Abraxane.

Bristol Myers Squibb Co. terlibat dalam penemuan, pengembangan, pemijakan, pembuatan, pemasaran, distribusi, dan penjualan produk biopharmaceutical. Perusahaan berkantor pusat di Princeton, New Jersey dan saat ini mempekerjakan 34.100 karyawan penuh waktu. Perusahaan terlibat dalam penemuan, pengembangan, dan penyampaian obat-obatan transformatif bagi pasien yang menghadapi penyakit serius di area: onkologi, hematologi, imunologi, kardiovaskular, neurosains, dan bidang lainnya. Platformnya mencakup obat-obatan yang disintesis secara kimia atau obat kecil, termasuk pengurai protein; obat-obatan yang dihasilkan dari proses biologis, yang disebut biologik; ADC, terapi sel CAR-T, dan terapi radiopharmaceutical. Obat kecil umumnya diberikan secara oral dalam bentuk tablet atau kapsul, meskipun mekanisme penyampaian obat lainnya juga digunakan. Biologik umumnya diberikan melalui injeksi atau infus intravena. Terapi sel CAR-T diberikan melalui infus intravena. Portofolio pertumbuhannya termasuk Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Opdualag, dan lainnya. Portofolio warisannya termasuk Eliquis, Revlimid, Pomalyst/Imnovid, Sprycel, dan Abraxane.

Tentang Bristol-Myers Squibb

Statistik Kunci